News

SanAir Technologies Laboratory Combines with Centek Laboratories

Expands Lab Testing Capabilities into Volatile Organic Compound (VOC) Air and Soil Gas Analysis

RICHMOND, Va., SanAir Technologies Laboratory, Inc. (SanAir) today announced its merger with Syracuse, NY-based Centek Laboratories, LLC (Centek), expanding its testing capabilities into VOCs using summa cannister and/or thermal desorption tubes technology (EPA Method TO-15 and TO-17) and analyzation of samples by GC/MS coupled with cryo-focusing or thermal desorption technology.

“Like SanAir, Centek is in the environmental laboratory analysis business but with additional capabilities not currently covered by our lab,” said SanAir President Sean P. McGlynn. “Centek has been a leader in vapor intrusion technology since they opened their doors in 2003, when they helped New York State’s Department of Health and its Department of Environmental Conservation change how samples were collected and tested, improving the technology to save money and increase detection limits in the ppb (part per billion) and ppt (part per trillion) detection range. They have brought that innovative, client-focused spirit to LEED®, WELL, IgCC Certification System; Biogas, Industrial Hygiene and Product Testing. We are excited to have Centek under the SanAir umbrella.”

The combined laboratories represent a total of 70 employees in Virginia, Ohio and New York.

Centek has been working in green and sustainable technology through indoor air quality (IAQ) testing since 2009 in conjunction with the U.S. Green Building Counsel (USGBC). Current testing programs include: LEED® IEQ Credit 3.2 2009 for New Construction and Major Renovations; LEED V4; LEED 4.1; WELL; and IgCC. Centek has been doing this testing throughout the United States, Canada and Mexico and is starting to open doors overseas.

Centek also has been testing BioGas reclamation systems in landfills and wastewater treatment plants (WWTP) throughout North America. The lab identifies a complete gas profile and determines the proper treatment processes needed to meet even the most stringent biogas specifications for use as a fuel.

“We are excited about the opportunities presented by our merger with SanAir,” said Russell Pellegrino, Centek’s Technical Director. “Our companies are similarly entrepreneurial but also grounded in our foundational principles of scientific accuracy and reliability in testing.

SanAir’s resources will help Centek continue to innovate and bring cost and time-efficient sampling solutions to our clients.”

The combination of the two laboratories caps a year of expansion for SanAir that includes moving into a new headquarters location in Greater Richmond (North Chesterfield) at the former Virginia Department of Emergency Management location, and the first fully operational and accredited year of industrial hemp and medical marijuana testing for the Company’s wholly-owned subsidiary, Sativa Testing Laboratories.

Read more here.

Recent News

05/08/2026

RIVANNA Receives FDA 510(k) Clearance for Accuro XV Musculoskeletal Ultrasound Imaging System

RIVANNA®, developer of AI-enabled clinical decision-support solutions, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the Accuro® XV Diagnostic Ultrasound System. The clearance marks a pivotal regulatory milestone for RIVANNA, authorizing commercial use of the Accuro XV for musculoskeletal imaging by qualified and trained healthcare professionals in hospital

05/06/2026

RoVa Labs Opens as Transformational Investment in Roanoke Region’s Innovation Economy

Leaders from Carilion Clinic, the City of Roanoke, Roanoke Blacksburg Innovation Alliance (RBIA), and Virginia Western Community College cut the ribbon on years of hard work with the opening of RoVa Labs, a 40,000-square-foot biotech incubator designed to accelerate commercialization, strengthen the Roanoke Innovation Corridor, and position the region as an emerging destination for life

05/04/2026

ISOThrive Reports Highly Statistically Significant Phase 2 Data for MHS-1031 in NERD PPI-Partial Responder Patients at DDW 2026

ISOThrive Inc. announced positive Phase 2 results for MHS-1031 treating NERD patients with incomplete response to proton pump inhibitors (PPIs), demonstrating statistically significant and clinically meaningful reductions in heartburn incidence, severity, and regurgitation. The company’s Chief Medical Officer is presenting these results at Digestive Disease Week (DDW) 2026 this week. NERD represents approximately 70% of